Ratios

		vs industry	vs history
P/B	6.82	SPEX's P/B is ranked higher than 93% of the 90 Companies in the Global Diagnostics & Research industry. ( Industry Median: 2.61 vs. SPEX: 6.82 )	SPEX' s 10-Year P/B Range Min: 0.28   Max: 67.04 Current: 6.82 0.28 67.04
P/S	34.10	SPEX's P/S is ranked higher than 67% of the 90 Companies in the Global Diagnostics & Research industry. ( Industry Median: 2.22 vs. SPEX: 34.10 )	SPEX' s 10-Year P/S Range Min: 0.64   Max: 66.24 Current: 34.1 0.64 66.24
EV-to-EBIT	-0.45	SPEX's EV-to-EBIT is ranked higher than 98% of the 90 Companies in the Global Diagnostics & Research industry. ( Industry Median: 17.90 vs. SPEX: -0.45 )	SPEX' s 10-Year EV-to-EBIT Range Min: 107.8   Max: 716.5 Current: -0.45 107.8 716.5

Valuation & Return

		vs industry	vs history
Price/Net Cash	9.8	SPEX's Price/Net Cash is ranked higher than 68% of the 90 Companies in the Global Diagnostics & Research industry. ( Industry Median: 10.65 vs. SPEX: 9.8 )	SPEX' s 10-Year Price/Net Cash Range Min: 0.7   Max: 53.1 Current: 9.8 0.7 53.1
Price/Net Current Asset Value	1.3	SPEX's Price/Net Current Asset Value is ranked lower than 62% of the 90 Companies in the Global Diagnostics & Research industry. ( Industry Median: 14.40 vs. SPEX: 1.3 )	SPEX' s 10-Year Price/Net Current Asset Value Range Min: 0.1   Max: 2.6 Current: 1.3 0.1 2.6
Price/Tangible Book	6.5	SPEX's Price/Tangible Book is ranked lower than 54% of the 90 Companies in the Global Diagnostics & Research industry. ( Industry Median: 4.00 vs. SPEX: 6.5 )	SPEX' s 10-Year Price/Tangible Book Range Min: 0.6   Max: 11.2 Current: 6.5 0.6 11.2
Price/Median PS Value	50.8	SPEX's Price/Median PS Value is ranked higher than 60% of the 90 Companies in the Global Diagnostics & Research industry. ( Industry Median: 0.90 vs. SPEX: 50.8 )	SPEX' s 10-Year Price/Median PS Value Range Min: 0.3   Max: 7.8 Current: 50.8 0.3 7.8
Earnings Yield (Greenblatt)	61.20	SPEX's Earnings Yield (Greenblatt) is ranked higher than 94% of the 90 Companies in the Global Diagnostics & Research industry. ( Industry Median: 5.60 vs. SPEX: 61.20 )	SPEX' s 10-Year Earnings Yield (Greenblatt) Range Min: 0.1   Max: 0.9 Current: 61.2 0.1 0.9
Forward Rate of Return (Yacktman)	-1022.61	SPEX's Forward Rate of Return (Yacktman) is ranked lower than 60% of the 90 Companies in the Global Diagnostics & Research industry. ( Industry Median: 0.46 vs. SPEX: -1022.61 )	SPEX' s 10-Year Forward Rate of Return (Yacktman) Range Min: -13.9   Max: -2.4 Current: -1022.61 -13.9 -2.4

Business Description

Spherix, Inc was incorporated as a Delaware corporation in 1967. It is a health science company and its main segments are Biospherics and Health Sciences. Biospherics segment is the Company's biotechnology research and development business, and Health Sciences segment is a engaged in providing technical and regulatory consulting services to biotechnology and pharmaceutical companies, as well as providing technical support for the Company's R&D activities. The Company has created two wholly-owned subsidiaries, Biospherics Incorporated and Spherix Consulting, Inc., for its two operating segments. The Company's patents are in the name of Biospherics Incorporated. The Company's Health Sciences contracts are in the name of Spherix Consulting, Inc. which provides management, strategic guidance, business development, marketing and other services to its subsidiaries. Biospherics is dedicated to development of pharmaceuticals which includes Triglycerides and Other Dyslipidemias; Diabetes. The Company does not operate or own any of its manufacturing facilities, and have purchased SPX-106 and D-tagatose from toll manufacturers who also produce other compounds. Health Sciences business provides technical and regulatory consulting services to biotechnology and pharmaceutical companies, as well as providing technical support for its R&D activities. It is also monitoring and directing the clinical trials for Biospherics. The Company has trademarked each of "Spherix" and "Biospherics." Competitors of Biospherics are other major pharmaceutical, chemical, consumer, and biotechnology companies; specialized firms; universities and other research institutions. Competitors of Health Sciences include larger companies with more resources. The Company's business activities are subject to a variety of Federal and state compliance, licensing, and certification requirements.
Company Website
SEC Reports

Industry:	Diagnostics & Research
Compare:	LH, ALR, DGX, LIFE, ENZ

» More Articles for SPEX

Headlines

Articles On GuruFocus.com

Spherix Inc. Reports Operating Results (10-Q) Aug 13 2010

Personalized Checklist